# Diabetes Hub Monitor Report — 2026-04-14

**Scheduled run:** automated review of latest script outputs and snapshot diffs.
**Previous report:** monitor_report_2026-04-13.md

---

## File System Status

| File | Last Modified | Status |
|------|---------------|--------|
| hub_monitor_report.md | 2026-04-14 02:04 | Fresh |
| clinical_trials_latest.json | 2026-04-14 02:04 | Fresh |
| clinical_trials_summary.md | 2026-04-14 02:04 | Fresh |
| pubmed_recent_latest.json | 2026-04-14 02:04 | Fresh |
| pubmed_recent_summary.md | 2026-04-14 02:04 | Fresh |
| literature_gap_data.json | 2026-04-13 15:44 | Current |
| literature_gap_report.md | 2026-04-13 15:44 | Current |
| Diabetes_Research_Tracker.xlsx | 2026-04-13 15:37 | Current |

Hub monitor flagged **368 result files older than 14 days**. These are mostly historical snapshot files (clinical_trials_snapshot_*, pubmed_recent_snapshot_*), which is expected. No critical refreshable file is stale.

Nothing missing — all four baseline data sources ran on schedule overnight.

---

## Clinical Trial Changes (2026-04-13 → 2026-04-14)

- **New trials:** 1
- **Status changes:** 2
- **New results posted:** 0
- Total trials tracked: 759 (151 T1D cure/cell, 71 T1D immunotherapy, 137 T2D novel, 220 devices, 255 recently completed with results)
- Recruiting: 262 | Phase 3 total: 116 | Phase 3 + RECRUITING: 44

### New trial
- **NCT07521475** — Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes (Insulet, 350 participants, DEVICE, start 2026-04-20). Fits the Diabetes Technology category and expands AID evidence into T2D; worth adding to the tracker.

### Status changes (NOT_YET_RECRUITING → RECRUITING)
- **NCT07317102** — Omnipod-5 French prospective multicenter real-world study (Optimal-B).
- **NCT07378956** — AI-SaMD funduscopy analysis in diabetic retinopathy screening.

### Key-organization Phase 3 RECRUITING (watchlist)
- Vertex: NCT04786262, NCT06832410 (both VX-880 in T1D — monitor for results readouts)
- Novo Nordisk: NCT07076199 (once-weekly insulin icodec)
- Eli Lilly: NCT07222137 and NCT07222332 (baricitinib in T1D — stage 3 delay & beta-cell preservation), NCT06739122 (pediatric dulaglutide), NCT06993792 and NCT06972472 (orforglipron obesity/OSA master protocols)

No Vertex / Lilly / Novo / Sana trials posted new results in the current snapshot.

---

## PubMed Highlights (lookback 30 days; 127 unique papers; +40 new vs 2026-04-13)

### Cross-domain papers (6) — highest priority
1. **PMID 41971325** — Multi-omics gut-microbiota ↔ sphingolipid interplay, neuroprotection in diabetic nephropathy. Domains: Biomarker / Microbiome / Multi-Omics. Directly relevant to Tier 1 Multi-Omics Biomarker Integration.
2. **PMID 41971387** — AI-driven personalized dietary recommendations (gastric-cancer high-risk). Domains: AI/ML / Microbiome / Multi-Omics.
3. **PMID 41971337** — ML comparison of saliva vs plaque microbiomes in T1D (Kuwaiti cohort). Domains: AI/ML / Microbiome.
4. **PMID 41974300** — Serum metabolomics + retinal-image biomarkers for diabetic retinopathy. Domains: AI/ML / Biomarker.
5. **PMID 41970998** — Whole-exome sequencing variants in diabetic nephropathy. Domains: Biomarker / Complications.
6. **PMID 41889910** — Donor-derived CD8 response in T1D islet therapy. Domains: T1D Stem Cell Cure / T1D Immunotherapy.

### Key therapy mentions
- **PMID 41913320** — Teplizumab: personalized medicine review (patient heterogeneity and response). No new mentions of zimislecel, orforglipron, retatrutide, CagriSema, or baricitinib in this 30-day window.

### Publication-volume notes
- LADA New Research (3) and Diabetes Drug Repurpose (4) remain chronically thin — consistent with Tier 1 contribution targets.
- Epigenetics dropped to 8 (vs 10 cap for most domains) — within normal variance.

---

## Gap Analysis Summary (from 2026-04-13 run)

Top 5 under-researched intersections (gap score 100, Tier 1 relevance flagged):

1. Beta Cell Regen × Health Equity (expected 1610.9; actual 0) — **Tier 1 alignment**
2. Insulin Resistance × Islet Transplant (expected 2130.2; actual 1)
3. Islet Transplant × GWAS / Polygenic (expected 1099.8; actual 0)
4. Islet Transplant × Personalized Nutrition (expected 376.8; actual 0)
5. Islet Transplant × Drug Repurposing (expected 371.9; actual 0) — **Tier 1 alignment (Drug Repurposing Computational Screening)**

Islet Transplant shows up in 4 of the top 5 gaps — a cross-cutting under-researched node. Aligns with Tier 1 "Clinical Trial Intelligence" (combination mapping across islet work) and "Drug Repurposing Computational Screening".

Gap data is 1 day old — no refresh needed.

---

## Breaking News (last 7 days, web check)

Significant items found:

- **FDA approved first generics of dapagliflozin (FARXIGA) tablets — April 7, 2026.** Multiple generic applicants approved for T2D glycemic control and HF hospitalization risk reduction. Lupin announced generic dapagliflozin-metformin combination approval April 8. *Evidence level: regulatory action (FDA press release).*
- **Lilly ACHIEVE-3 readout (orforglipron):** Phase 3 showed superior A1C reduction vs oral semaglutide; 73.6% greater relative weight loss at highest dose. First oral small-molecule GLP-1 RA to complete Phase 3 without food/water restrictions. *Evidence level: sponsor press release + trade-press coverage; peer-reviewed publication pending.*

Both items align with active watchlist trials (orforglipron master protocols NCT06993792 / NCT06972472 already tracked). Consider logging the ACHIEVE-3 readout in the tracker under "Notable Trials to Watch" — it is currently empty.

No FDA actions on Vertex VX-880 / zimislecel, Sana Biotechnology islet programs, teplizumab sNDA, or retatrutide / CagriSema this week.

---

## Recommended Actions

1. **Update tracker** with new trial **NCT07521475** (Omnipod fully closed-loop, T2D) and flag status flips for **NCT07317102** and **NCT07378956**.
2. **Populate "Notable Trials to Watch"** table in `clinical_trials_summary.md` — it is currently empty. At minimum add Vertex VX-880 (NCT04786262, NCT06832410), Lilly baricitinib T1D (NCT07222137, NCT07222332), and Lilly orforglipron master protocols.
3. **Review cross-domain paper PMID 41971325** (gut microbiota ↔ sphingolipid multi-omics in diabetic nephropathy) — fits Tier 1 Multi-Omics Biomarker Integration and Tier 1 Literature Synthesis.
4. **Add ACHIEVE-3 orforglipron readout** as an entry in tracker / Research_Findings_Summary.md, tagged evidence level = sponsor press release (pending peer review).
5. **Add dapagliflozin generic approval (FDA, 2026-04-07)** as a regulatory-action note in the tracker.
6. **No re-runs required today:** gap analysis (1 day old), clinical trials and PubMed snapshots all fresh as of 2026-04-14 02:04.
7. **Consider refreshing** `agent_state.json`, `evidence_network.json`, `gap_evidence.json`, `pmid_verification.json` — all last modified 2026-04-13 03:09; not stale yet but approaching 14-day horizon soon.

---

*Automated review. No files modified. All findings traceable to snapshots in Analysis/Results/.*

Sources:
- [FDA Approves First Generic Dapagliflozin Tablets (FDA)](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-approves-first-generic-dapagliflozin-tablets)
- [FDA Approves First Generic Dapagliflozin to Reduce HF Hospitalization Risk (AJMC)](https://www.ajmc.com/view/fda-approves-first-generic-dapagliflozin-to-reduce-hf-hospitalization-risk-in-type-2-diabetes)
- [ACHIEVE-3: Orforglipron Superior to Semaglutide for T2D in Phase 3 (HCPLive)](https://www.hcplive.com/view/achieve-3-orforglipron-superior-to-semaglutide-for-type-2-diabetes-in-phase-3-trial)
- [Lilly orforglipron Phase 3 results (Eli Lilly investor release)](https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically)
